483
BioMylz Pvt. Ltd.FDA 483 - BioMylz Pvt. Ltd. - February 07, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of BioMyz Pvt. Ltd. in Bangalore, India, from February 3-7, 2020, revealed extensive deficiencies across its drug manufacturing operations. The firm failed to establish and follow critical written procedures for quality control, production, equipment maintenance, and employee training. These issues indicate a systemic lack of adherence to current Good Manufacturing Practices (cGMP) regulations.
Open in Dashboard
ID · c7e2694d-628f-437d-bdcf-9a90e2ef0a3a